MedTrace Logo

Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands

NCT02602275 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-06-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to explore the effect of Neurexan® on the brain response when participants undergo an emotional stressful condition in verum compared to placebo.

Conditions

  • Acute Stress Reaction

Interventions

DRUG

Neurexan

0.6 mg / tablet

DRUG

Placebo

Neurexan-matched Placebo tablet

Sponsors & Collaborators

  • Biologische Heilmittel Heel GmbH

    lead INDUSTRY

Principal Investigators

  • Martin Walter, PD Dr Med. · Clinical Affective Neuroimaging Laboratory, Univ. Magdeburg, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
31 Years
Max Age
59 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02602275 on ClinicalTrials.gov